PT  - JOURNAL ARTICLE
AU  - KAZUTOSHI ISOBE
AU  - YOSHINOBU HATA
AU  - KUNIHIKO KOBAYASHI
AU  - NAO HIROTA
AU  - KEITA SATO
AU  - GO SANO
AU  - KEISHI SUGINO
AU  - SUSUMU SAKAMOTO
AU  - YUJIRO TAKAI
AU  - KAZUTOSHI SHIBUYA
AU  - KEIGO TAKAGI
AU  - SAKAE HOMMA
TI  - Clinical Significance of Circulating Tumor Cells and Free DNA in Non-small Cell Lung Cancer
DP  - 2012 Aug 01
TA  - Anticancer Research
PG  - 3339--3344
VI  - 32
IP  - 8
4099  - http://ar.iiarjournals.org/content/32/8/3339.short
4100  - http://ar.iiarjournals.org/content/32/8/3339.full
SO  - Anticancer Res2012 Aug 01; 32
AB  - Aim: This pilot study assessed correlations between circulating tumor cells (CTCs) and circulating free DNA (cfDNA) of metastatic non-small cell lung cancer (NSCLC) after acquisition of resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Patients and Methods: CTCs were counted using the CellSearch system (Veridex). cfDNA was analyzed for EGFR mutation status by the Cycleave real-time PCR assay. Results: Twenty-four patients participated in this study. CTCs were detected in 8 of 24 cases (33.3%), at a mean of 2.6 CTCs per 7.5 ml blood (range: 1-24). EGFR mutations in cfDNA were detected in 6 out of 24 cases (25%). The EGFR mutation detection rates in cfDNA were significantly higher in patients with ≥2 CTCs per 7.5 ml (100%) than in those with <2 CTCs per 7.5 ml (10%) (p=0.0001). Conclusion: The presence of CTCs was correlated with the positivity of EGFR mutation in cfDNA.